Peer-Reviewed Study Validates HEMOTAG as a Non-Invasive Tool to Guide Treatment in Acutely Decompensated Heart Failure
FOR IMMEDIATE RELEASE Boca Raton, FL — Aventusoft, the company behind HEMOTAG®, a breakthrough Heart Failure management system, is proud to announce the publication of a peer-reviewed study in Cardiovascular…
HEMOTAG® Completes AgeTech Collaborative Accelerator and Joins AgeTech Collaborative™ Ecosystem to Transform Heart Failure Care
FOR IMMEDIATE RELEASE Boca Raton, FL — Aventusoft, the company behind HEMOTAG®, Full-Spectrum Heart Failure Management System, proudly announces its successful completion of the AgeTech Collaborative™ from AARP accelerator program….
HEMOTAG selected for prestigious MedTech Innovator 2025 Asia Pacific Accelerator Cohort
FOR IMMEDIATE RELEASEBoca Raton, FL — Aventusoft, the company behind HEMOTAG®, a breakthrough Heart Failure management system, is proud to announce its acceptance into the MedTech Innovator 2025 Asia Pacific…
Aventusoft/HEMOTAG Takes First Place in the Bio Pitch During BioFlorida 2023
FOR IMMEDIATE RELEASE October 13, 2023 Ponte Vedra, FL – HEMOTAG, a non-invasive and portable structural heart health monitoring device, took the first place on the Bio Pitch during the…
Aventusoft to Launch HEMOTAG® Vitals at the Prestigious HLTH Conference 2023, Following Selection by NIH
PRESS RELEASE FOR IMMEDIATE RELEASE [Boca Raton, FL, September 14, 2023] – Aventusoft, a pioneering research-driven company dedicated to developing innovative products that address heart conditions by challenging established paradigms,…